TWENTY-FIRST
`
`Annual Meeting of the
`
`American Society of Clinical Oncology
`
`May 19-21, 1985
`
`PROCEEDINGS
`
`Houston, Texas
`
`
`
`Scientific Proceedings
`
`Abstracts
`
`NUS
`
`Biomarkers, Diagnosis, Etiology, Epidemiology
`Cancer Prevention
`
`Clinicai Pharmacology (Adult and Pediatric)
`Clinical Trials
`Breast
`Gastrointestinal Tract
`Genitourinary Tract (Other Than Gynecology)
`Gynecological Tumors
`Head and Neck, Sarcoma, Melanoma, and Other Solid
`Tumors
`
`Leukemia (Adult and Pediatric)
`Lung
`Lymphoma (Adult and Pediatric)
`Other Hematological Tumors
`immunology and Biological Response Modifiers
`Pediatric Solid Tumors
`Psychosocial Aspects of Cancer
`Radiation Biology
`Supportive Care, Infectious Disease, Nutrition
`Surgical Oncology
`Author index
`
`Subject index
`
`1
`
`7
`23
`
`25
`
`53
`76
`96
`1 12
`126
`
`154
`175
`197
`215
`218
`234
`247
`254
`256
`275
`279
`
`291
`
`Volume 4 o March 1985
`
`AstraZeneca Exhibit 2146 p. 1
`InnoPharma Licensing LLC V. AstraZeneca AB IPR2017-00905
`
`

`

`Proceedings of the
`American Society of Clinical Oncology
`
`
`AMERICAN SOCIETY OF CLINICAL ONCOLOGY,
`
`INC.
`
`OFFICERS
`
`1 984-1 985
`
`President, Sydney E. Salmon
`
`President-Elect, John R. Durant
`
`Immediate Past President, Philip S. Schein
`
`Secretary-Treasurer, David L. Ahmann
`
`BOARD OF DIRECTORS
`
`Martin D. Abeloff
`Bruce A. Chabner
`Charles A. Coltman, Jr.
`Alfred Van Horn ill
`Executive Director
`
`Eli Glatstein
`Sharon B. Murphy
`Steven A. Rosenberg
`
`
`
`Editorial Staff
`
`Margaret Foti, Managing Editor
`Mary Anne Mennite, Assistant Managing Editor
`Heide M. Pusztay, Senior Staff Editor
`
`Denise E. Grant
`Elizabeth A. Moore
`Ellen M. McDonald
`Rosemary Griffin
`Margaret A. Crawford
`Lilliane M. Chouinard
`Kimberly A. Collins
`Sandra E. Pattie
`William A. Borrelle
`Diane E. Nolte
`Rita laquinto
`Aileen M. McHugh
`
`
`Copyright 1985 by the American Society of Clinical Oncology. Printed for the American Society of Clinical
`Oncology. by Waverly Press, lnc., Baltimore, MD 21202.
`
`AstraZeneca Exhibit 2146 p. 2
`
`
`
`

`

`
`rmsmmnax mam Dratzctndhv Cawmgm‘awmfl: 1m 3 cm}
`
`
`
`
`
`
`BREAST
`
`C~217
`TREATMENT OF ADVANCED BREAST CANCER WITH MEDROXY—
`PROGESTERONE ACETATE.
`A phase III evaluation of the dose—response relaw
`tionship at two dose levels?
`
`cfiosefiflfiouridsen, B.Engelsman, M.Nooi, R.Syl~
`Vester, NqRotmensz for the EORTC Breast Cancer
`Group, Finsen Institute; 49 Strandboulevarden,
`2100 Copenhagen Q), Denmark»
`medroxyprogesterone acetate (MPA) binds specifiu
`Cally to the progesterone receptor in the human
`mammary tumor cytosol, but it has also affinity
`for the glucocorticoid and the androgen recegtors.
`It is therefore conceivable,
`that MPA given at
`high doses may affiect mammary tumor growth by bin—
`ding not only to progesterone, but also to the ot~
`her
`two receptors. The EORTC Breast Cancer Group
`has therefore conducted a randomized dose—response
`trial comparing the contineous oral administration
`of 300 and 900 mg of MPA daily. Patients with ad»
`vanced measurable cancer, clinically resistant to
`prior cytotoxic and/or endocrine therapy were eli—
`gible for the studyv
`the overall response
`Among 201 evaluable patients,
`rate was 23 and 16 % in patients treated at the
`high and low dose level, respectively (9:0.08).
`The time to progression was significantly longer
`in those treated with the high dose (peo.o2),Re—
`sponse duration and survival was insignificantly
`prolonged in those receiving high dose MPA.
`The results indicate a dose response relationship
`for treatment with progestins=
`
`C-218
`STUDY OF HUMAN BREAST CANCER IN SOFT AGAR CULTURE
`T. K. Banerjee, Jo J. Marx; Jr., SQ K. Spencer, Bi J. Ault,
`Don Stoiber, S; M, Sajjad, Marshfield Clinic and Mershfield
`Medical Foundation9 Mershfield, N1 54449a
`(Sponsored by
`T. K. Banerjee}
`One hundred and forty three malignant samples (67
`tissues and 76 fluids) from 101 women with breast cancer
`were subjected to human tumor clanegenic assay (HTCA)i
`Eighteen samples were not plated because of insufficient
`tumor cells and 6 culture plates were contaminated with
`bacterial or fungal infection. Sixty three of 119 (53%)
`samples had adequate growth (230 colonies). Eleven samples
`had inadequate growth (<30 colonies)a
`Twenty seven of 56
`tissue samples (ass) had adequate growth and 6 had
`inadequate growth. Of these 56 samples 30 were taken from
`primary breast tumors and 26 were from metastatic sources“
`There were 53.3% (létBO) of primary scurees and 46% (12/26)
`Of metastatic sources that grew adequately,
`The pleural
`fluid samples grew 65% (SO/4%) and the ascitic samples 29%
`(5/1?) adequatelya Eleven of twenty two of estrogen
`receptor (ER) positive and 12/20 ER negative tissue
`specimens grew.
`It appeared that the colony numbers on an
`average was lower in ER positive tumors with 2181 le/ng
`0f protein values.
`The colony growths of 2 malignant
`fluids were confirmed as malignant
`tumor cells by electron
`microscoPic examination.
`No correlation with histiologic
`grading and colony growth can be made, When receptor
`results were plotted against sensitivity to various
`hormonal agents there were a great deal of variations in
`individual samples,
`In 2 instances, even though the ER
`Was negative there was wide range of sensitivity in the
`HTCA against various hormonal agents restedw HTCA results
`0f 6 tissue and 18 fluid samples were evaluated clinically.
`Twenty three percent of those shown to be sensitive,
`reaponded to the indicated drug and ?7% thought
`to be
`resistant actually were.
`
`C-219
`PRDSPECTIVE COMPARISON OF COMBINATIQN CHEMOTHERAPY WITH OR
`WITHOUT A PROSTAGLANDIN SYNTHESIS INHIBITUR IN ADVANCES
`BREAST ClNCER. A. Khojasteh, R‘D, Reynolds, A.R, Garcia,
`E,P, Mitchell9 J, Walter, N90. Ansong Ellis Fischel Cancer
`Center, Columbia9 Missouri 65203,
`The safety and efficacy of mitamycin—C (MTG) and
`continuously infused vinblastine (VLB)
`therapy in metastatic
`breast cancer have previously been demonstrated.
`The
`ability of prostaglandin synthesis inhibitors (PSI) to
`reduce growth of mammary carcinoma has recently been
`described in experimental and clinical settings.
`An ongoing
`phase III trial has been conducted to determine the impact
`of a FSI (ibuprofen) on the response of advanced breast
`carcinoma (BC)
`to a combined chemotherapy (VLB + MTG)
`regimen. At the time of this evaluation 13 gretreated
`females with measurable BC (age range: 29 to 64 years; 2
`premenopausal,
`11 postmenopausal) have entered in this
`studyi
`7 patients received VLB (195 mgfmz l.V. over 24
`hours on days l~5> + MTG (10 mg/m2 I.V. on day 3) every
`five weeks,
`6 patients were treated with aforementioned
`chemotherapy plus ibuprofen (1800 mg, p,o. daily). Both
`treatment groups were comparable in age, menoyausal and
`hormonal receptor status and number of courses of therapy.
`The treatment was well tolerated by most patients.
`The
`overall partial response following 2 to 8 courses of the
`therapy was observed in 5f13 patients, Stabilization of
`measurable lesions for 10 to 37 weeks was noted in 3/13
`patients.
`The remaining patients (3/13) failed to respond.
`The preliminary results suggest that,
`in the limited number
`of studied cases9 ibuprofen at the current dose schedule
`does not contribute to the improvement of response rate to
`chemotherapy. More extensive trails of the PSI combined
`with chemotherapy regimens, with specific reference to in-
`cidence of osseous metastasis, bone pain, hyperealeemia
`and therapeutic index of ancineoplastic agents in connection
`with chemotherapy related mucosal damage, are in process.
`
`C—220"
`ADJNAM TREATMENT WITH TN’UXIFEN IN WM PATIENTS NIH-2
`HIGH RISK Eli-EAST CW: 78 MZNTHS CF LIFE TPBLE ANALYSIS,
`HJ‘ Mricem? Ci Rose, SM. Thorpe, 3. Wm, M. BJJ'LUFErt—Yrfita
`and KM; Andersen for the Denies Breast Cancer {Imperative Gran (m),
`Fiasco Insti’rube3 0,? Stmarrcbculevarder:5 21m Copsrhagen El, Denmark.
`
`This mtmide trial in:le mm (8.9. 5 years of
`mostasia) patients less the: 80 years of age with primary h1g1 risk
`{egg node positive) breast caviar. Primary treatrrmt was total mates»
`may and axillary sampling Follow by radiotlerapy (R?) to the scar
`and regional 1W. Fran angst 1977 to mvenber 1982 1650 patients
`mtered ire trial: 821 ms rad-mixed to no further therapy (RT-group)
`and 829 to treatma’lt For 1 year with tamifeh 30 mg daily (mum—9mm.
`At 6 years life male analysis the recurrence Free survival (W5)
`is we in the RT-y-TN'Lgrup and 4:395 in the RI—gmn (mamas). mival
`is idwtical (5136) in the two grape ($320.53). The data have been
`further analysed in relation to pmgmtic factors e.g. age, degree of
`armlesie, tumr size and umber of positive nodes. The RFS is lower
`in all sheets of patients treated with RT 4» TM, but the difference
`is statistically sig‘lifica'rt only in patients 50—59 yws of age? with
`tumors of grade I, or with a or mare preitive lgmrhodes.
`Estmgmresepter <ER) mtratim were measured in a sheet of
`292 of the patients. A cut-off limit of lo fund/Hg cytcsol protein
`simificmtly distirgiietes between retimts with long RPS and those
`wfifbeerly recurmafi disease.Patients wiflaER content below loo finolfig
`did not benefit from the emacr‘me them my dose with amtre
`time above 100 fml/ng fed a sigfificmtly longer RFS. 19B of the
`grienasnaipnxxetemxe naxp x (Rfi) asennketiae as we fif
`positive patimts treated with TM did sigfif'icmtly better than The
`cmtrol 91w (920.015).
`Evaluation of the clinical results as of April 1985 will be area
`eatei
`
`
`
`
`
`PROCEEDINGS OF ASCO VOL. 4 MARCH 1985
`57
`
`
`
`AStraZeneca Exhibit 2146 p. 3
`
`